Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6108127rdf:typepubmed:Citationlld:pubmed
pubmed-article:6108127lifeskim:mentionsumls-concept:C0699870lld:lifeskim
pubmed-article:6108127lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:6108127lifeskim:mentionsumls-concept:C0005320lld:lifeskim
pubmed-article:6108127lifeskim:mentionsumls-concept:C0427728lld:lifeskim
pubmed-article:6108127lifeskim:mentionsumls-concept:C1313904lld:lifeskim
pubmed-article:6108127lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:6108127lifeskim:mentionsumls-concept:C0231491lld:lifeskim
pubmed-article:6108127lifeskim:mentionsumls-concept:C0013125lld:lifeskim
pubmed-article:6108127lifeskim:mentionsumls-concept:C1709518lld:lifeskim
pubmed-article:6108127lifeskim:mentionsumls-concept:C0242564lld:lifeskim
pubmed-article:6108127pubmed:issue5lld:pubmed
pubmed-article:6108127pubmed:dateCreated1981-2-26lld:pubmed
pubmed-article:6108127pubmed:abstractText1 In normal subjects, intravenous betaxolol given in doses which inhibited the tachycardia of exercise failed to affect the peak expiratory flow rate. 2 From 2 to 48 h after administration of 150 micrograms/kg in four normal subjects, there was no significant difference between the blood levels, whether given orally or intravenously. 3 At all times, heart rate and blood pressure, at rest and during exercise, were reduced equally after administration by both routes, but the area under the curve of exercise heart rate against time was significantly smaller (P < 0.05) after intravenous drug. 4 The absolute bioavailability of betaxolol was 89 +/- 5%.lld:pubmed
pubmed-article:6108127pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6108127pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6108127pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6108127pubmed:languageenglld:pubmed
pubmed-article:6108127pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6108127pubmed:citationSubsetIMlld:pubmed
pubmed-article:6108127pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6108127pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6108127pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6108127pubmed:statusMEDLINElld:pubmed
pubmed-article:6108127pubmed:monthNovlld:pubmed
pubmed-article:6108127pubmed:issn0306-5251lld:pubmed
pubmed-article:6108127pubmed:authorpubmed-author:MorselliP LPLlld:pubmed
pubmed-article:6108127pubmed:authorpubmed-author:TurnerPPlld:pubmed
pubmed-article:6108127pubmed:authorpubmed-author:WarringtonS...lld:pubmed
pubmed-article:6108127pubmed:authorpubmed-author:KilbornJ RJRlld:pubmed
pubmed-article:6108127pubmed:authorpubmed-author:BianchettiGGlld:pubmed
pubmed-article:6108127pubmed:issnTypePrintlld:pubmed
pubmed-article:6108127pubmed:volume10lld:pubmed
pubmed-article:6108127pubmed:ownerNLMlld:pubmed
pubmed-article:6108127pubmed:authorsCompleteYlld:pubmed
pubmed-article:6108127pubmed:pagination449-52lld:pubmed
pubmed-article:6108127pubmed:dateRevised2010-9-14lld:pubmed
pubmed-article:6108127pubmed:meshHeadingpubmed-meshheading:6108127-...lld:pubmed
pubmed-article:6108127pubmed:meshHeadingpubmed-meshheading:6108127-...lld:pubmed
pubmed-article:6108127pubmed:meshHeadingpubmed-meshheading:6108127-...lld:pubmed
pubmed-article:6108127pubmed:meshHeadingpubmed-meshheading:6108127-...lld:pubmed
pubmed-article:6108127pubmed:meshHeadingpubmed-meshheading:6108127-...lld:pubmed
pubmed-article:6108127pubmed:meshHeadingpubmed-meshheading:6108127-...lld:pubmed
pubmed-article:6108127pubmed:meshHeadingpubmed-meshheading:6108127-...lld:pubmed
pubmed-article:6108127pubmed:meshHeadingpubmed-meshheading:6108127-...lld:pubmed
pubmed-article:6108127pubmed:meshHeadingpubmed-meshheading:6108127-...lld:pubmed
pubmed-article:6108127pubmed:meshHeadingpubmed-meshheading:6108127-...lld:pubmed
pubmed-article:6108127pubmed:meshHeadingpubmed-meshheading:6108127-...lld:pubmed
pubmed-article:6108127pubmed:meshHeadingpubmed-meshheading:6108127-...lld:pubmed
pubmed-article:6108127pubmed:meshHeadingpubmed-meshheading:6108127-...lld:pubmed
pubmed-article:6108127pubmed:meshHeadingpubmed-meshheading:6108127-...lld:pubmed
pubmed-article:6108127pubmed:year1980lld:pubmed
pubmed-article:6108127pubmed:articleTitleBlood concentrations and pharmacodynamic effects of betaxolol (SL 75212) a new beta-adrenoceptor antagonist after oral and intravenous administration.lld:pubmed
pubmed-article:6108127pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6108127lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6108127lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6108127lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6108127lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6108127lld:pubmed